Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HCC1143 | TNBC | Basal A | Doxorubicin | TOP2 | TOP | 0.00589 | uM | 9233.121 | 1.0776 | 1.1643 | 0.9468 | |
| HCC1143 | TNBC | Basal A | Doxorubicin | TOP2 | TOP | 0.0294 | uM | 9233.121 | 1.0018 | 1.0037 | 0.9468 | |
| HCC1143 | TNBC | Basal A | Doxorubicin | TOP2 | TOP | 0.147 | uM | 9233.121 | 0.8213 | 0.6246 | 0.9468 | |
| HCC1143 | TNBC | Basal A | Doxorubicin | TOP2 | TOP | 0.736 | uM | 9233.121 | 0.5114 | -0.0151 | 0.9468 | |
| HCC1143 | TNBC | Basal A | Doxorubicin | TOP2 | TOP | 3.68 | uM | 9233.121 | 0.2095 | -0.6163 | 0.9468 | |
| HCC1143 | TNBC | Basal A | Doxorubicin | TOP2 | TOP | 18.4 | uM | 9233.121 | 0.1904 | -0.6530 | 0.9468 | |
| HCC1143 | TNBC | Basal A | Doxorubicin | TOP2 | TOP | 92 | uM | 9233.121 | 0.0470 | -0.9209 | 0.9468 | |
| HCC1187 | TNBC | Basal A | Doxorubicin | TOP2 | TOP | 0.000221 | uM | 7812.047 | 1.0648 | 1.1200 | 1.0776 | |
| HCC1187 | TNBC | Basal A | Doxorubicin | TOP2 | TOP | 0.0011 | uM | 7812.047 | 0.9559 | 0.9181 | 1.0776 | |
| HCC1187 | TNBC | Basal A | Doxorubicin | TOP2 | TOP | 0.00552 | uM | 7812.047 | 0.9948 | 0.9904 | 1.0776 | |
| HCC1187 | TNBC | Basal A | Doxorubicin | TOP2 | TOP | 0.0276 | uM | 7812.047 | 0.9928 | 0.9866 | 1.0776 | |
| HCC1187 | TNBC | Basal A | Doxorubicin | TOP2 | TOP | 0.138 | uM | 7812.047 | 0.8927 | 0.8000 | 1.0776 | |
| HCC1187 | TNBC | Basal A | Doxorubicin | TOP2 | TOP | 0.69 | uM | 7812.047 | 0.3084 | -0.3286 | 1.0776 | |
| HCC1187 | TNBC | Basal A | Doxorubicin | TOP2 | TOP | 3.45 | uM | 7812.047 | 0.3895 | -0.1662 | 1.0776 | |
| HCC1187 | TNBC | Basal A | Doxorubicin | TOP2 | TOP | 17.2 | uM | 7812.047 | 0.3293 | -0.2867 | 1.0776 | |
| HCC1187 | TNBC | Basal A | Doxorubicin | TOP2 | TOP | 86.2 | uM | 7812.047 | 0.3898 | -0.1658 | 1.0776 | |
| HCC1187 | TNBC | Basal A | Doxorubicin | TOP2 | TOP | 0.000221 | uM | 9244.034 | 1.2704 | 1.9252 | 0.6294 | |
| HCC1187 | TNBC | Basal A | Doxorubicin | TOP2 | TOP | 0.0011 | uM | 9244.034 | 0.9944 | 0.9821 | 0.6294 | |
| HCC1187 | TNBC | Basal A | Doxorubicin | TOP2 | TOP | 0.00552 | uM | 9244.034 | 1.0960 | 1.3135 | 0.6294 | |
| HCC1187 | TNBC | Basal A | Doxorubicin | TOP2 | TOP | 0.0276 | uM | 9244.034 | 0.8458 | 0.5329 | 0.6294 | |
| HCC1187 | TNBC | Basal A | Doxorubicin | TOP2 | TOP | 0.138 | uM | 9244.034 | 0.6074 | -0.0943 | 0.6294 | |
| HCC1187 | TNBC | Basal A | Doxorubicin | TOP2 | TOP | 0.69 | uM | 9244.034 | 0.0267 | -0.9937 | 0.6294 | |
| HCC1187 | TNBC | Basal A | Doxorubicin | TOP2 | TOP | 3.45 | uM | 9244.034 | 0.0378 | -0.9890 | 0.6294 | |
| HCC1187 | TNBC | Basal A | Doxorubicin | TOP2 | TOP | 17.2 | uM | 9244.034 | 0.0259 | -0.9940 | 0.6294 | |
| HCC1187 | TNBC | Basal A | Doxorubicin | TOP2 | TOP | 86.2 | uM | 9244.034 | 0.0042 | -0.9997 | 0.6294 |